Cargando…
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
Autores principales: | Crauwels, HM, van Schaick, E, van Heeswijk, RPG, Vanveggel, S, Boven, K, Vis, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112967/ http://dx.doi.org/10.1186/1758-2652-13-S4-P186 |
Ejemplares similares
-
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
por: Cohen, C, et al.
Publicado: (2010) -
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
por: Nelson, M, et al.
Publicado: (2010) -
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012) -
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017) -
Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)